<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956967</url>
  </required_header>
  <id_info>
    <org_study_id>ZOB-NIV-1504</org_study_id>
    <secondary_id>C1121004</secondary_id>
    <nct_id>NCT02956967</nct_id>
  </id_info>
  <brief_title>Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia</brief_title>
  <official_title>Home Administration Of Nivestimtm In The Primary Prophylaxis Of Chemotherapy-induced Febrile Neutropenia Non-interventional, Observational, Prospective Study Short Name: Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional, non-comparative, national, multi-site, single-arm prospective
      observational study to investigate home administration of Nivestim in the primary prophylaxis
      of chemotherapy-Induced febrile neutropenia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Actual">December 12, 2016</completion_date>
  <primary_completion_date type="Actual">December 12, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean age of patients enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients enrolled with any previous or ongoing significant comorbidities</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage and type of haematological malignancy diagnosed</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage and type of solid tumor diagnosed</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time since diagnosis of solid tumour or malignant haematological tumour prior to enrollment</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of males and females enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean weight of patients enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean body mass index (BMI) of patients enrolled</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients receiving chemotherapy prior to enrollment</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean duration and type of chemotherapy received during study</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who have a positive satisfaction with Nivestim</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' overall rating of satisfaction with Nivestim</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of Nivestim packaging</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
    <description>Evaluation of Nivestim™ packaging Nivestim™ handling instructions Manageability of Nivestim™ syringes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of tolerability of Nivestim at the injection site</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>Patients' rating of Tolerability of Nivestim™ at the injection site Painfulness of the needle insertion into the skin Overall tolerability of the subcutaneous injection of Nivestim™</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who experience neutropenia</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who experience an infection</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in absolute neutrophil count</measure>
    <time_frame>Baseline up to approximately 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">171</enrollment>
  <condition>Non-Interventional Study</condition>
  <arm_group>
    <arm_group_label>Patients receiving Nivestim</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Overall satisfaction questionnaires of home use of Nivestim</intervention_name>
    <arm_group_label>Patients receiving Nivestim</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults undergoing cytotoxic chemotherapy treated prophylactically with NivestimTM in order
        to reduce the duration of neutropenia and to reduce the incidence of chemotherapy-induced
        FN.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients ≥ 18 years

          -  Declaration of informed consent signed by patient

          -  Patients with a solid tumour or with a malignant haematological tumour

          -  Patients who have been prescribed cytotoxic chemotherapy, irrespective of current
             cycle

          -  GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last
             three months before enrolment

          -  Patients starting primary prophylactic treatment using NivestimTM either to shorten
             the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN

        Exclusion Criteria:

          -  Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)

          -  Patients who are hypersensitive to one of the excipients of NivestimTM

          -  Patients not undergoing chemotherapy

          -  Patients being treated curatively or as secondary prophylaxis with G-CSF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Office of Manfred Welslau</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Martine Klausmann</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Bernhard Heinrich</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Reinhard Musch</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Peter Klare</name>
      <address>
        <city>Berlin</city>
        <zip>13595</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Ute Bückner</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Peter Jungberg</name>
      <address>
        <city>Chemnitz</city>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Ivo Azeh</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Peter von Wussow</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Volker Petersen</name>
      <address>
        <city>Heidenheim</city>
        <zip>89518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Lars-Jörgen Hahn</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Michael Neise</name>
      <address>
        <city>Krefeld</city>
        <zip>47804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Gunther Rogmans</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Peter Anhut</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Albrecht Kretzschmar</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Nidal Gazawi</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Udo Hieber</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Christoph Salat</name>
      <address>
        <city>München</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Christian Lerchenmüller</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Burkhard Otremba</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Julian Topaly</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Andre-Robert Rotmann</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Rene Schubert</name>
      <address>
        <city>Scheibenberg</city>
        <zip>09481</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Matthias Groschek</name>
      <address>
        <city>Stolberg</city>
        <zip>52222</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Carsten Hielscher</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Thomas Kuhn</name>
      <address>
        <city>Stuttgart</city>
        <zip>70193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Ortwin Klein</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Interventional Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 11, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

